menu
    • menu

    Company profile for Thetis Pharmaceuticals

    NEW Drugs in Dev: 2
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Thetis is developing new medicines derived from a class of potent, naturally-occurring signaling molecules called Resolvins that promote immune homeostasis. Our disease targets -- inflammatory bowel disease (IBD) and major solid tumor cancers-- represent high unmet medical needs. Thetis is led by an experienced team of industry veterans, complemented by world-class scientific advisors. This combination is driving development...
    Thetis is developing new medicines derived from a class of potent, naturally-occurring signaling molecules called Resolvins that promote immune homeostasis. Our disease targets -- inflammatory bowel disease (IBD) and major solid tumor cancers-- represent high unmet medical needs. Thetis is led by an experienced team of industry veterans, complemented by world-class scientific advisors. This combination is driving development of innovative medicines for complex medical conditions.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Thetis PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Essex, Connecticut
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.thetispharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/thetis-pharmaceuticals-llc/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    euroPLX 90 Lisbon

    Not Confirmed

    envelop Contact Supplier

    euroPLX 90 Lisbon

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Thetis Pharma Expands Advisory Board With IBD Experts
    Thetis Pharma Expands Advisory Board With IBD Experts

    12 Feb 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-02-12/thetis-pharmaceuticals-expands-scientific-advisory-board-with-leading-experts-in-inflammatory-bowel

    PHARMIWEB
    12 Feb 2026
    Share Share
    Thetis Pharmaceuticals Reveals TP-317 Data at DDW 2025
    Thetis Pharmaceuticals Reveals TP-317 Data at DDW 2025

    05 May 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250505954671/en/Thetis-Pharmaceuticals-Presents-New-Preclinical-and-Clinical-Data-forTP-317-at-DDW-2025

    BUSINESSWIRE
    05 May 2025
    Share Share
    Thetis Presents TP-317 Preclinical, Clinical Data At ECCO 2025
    Thetis Presents TP-317 Preclinical, Clinical Data At ECCO 2025

    19 Feb 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250219233825/en

    BUSINESSWIRE
    19 Feb 2025
    Share Share
    Thetis Secures 8.975M To Advance TP-317 Ph 1b In Ulcerative Colitis
    Thetis Secures 8.975M To Advance TP-317 Ph 1b In Ulcerative Colitis

    09 Jan 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250109823925/en

    BUSINESSWIRE
    09 Jan 2025
    Share Share
    Thetis Pharmaceuticals Appoints Fabio Cataldi to Advisory Roles
    Thetis Pharmaceuticals Appoints Fabio Cataldi to Advisory Roles

    14 Nov 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241114842177/en

    BUSINESSWIRE
    14 Nov 2024
    Share Share
    Thetis Pharmaceuticals Reports Positive Phase 1a Results for TP-317
    Thetis Pharmaceuticals Reports Positive Phase 1a Results for TP-317

    31 Oct 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241031890209/en

    BUSINESSWIRE
    31 Oct 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search